Psilocybin
Tryp Partners With Hospital For Psilocybin Study For IBS
The market for IBS treatments is estimated to grow to $4.7 billion by 2030.
The post Tryp Partners With Hospital For Psilocybin Study For IBS appeared…
Tryp Therapeutics, Inc. (CSE:TRYP) (OTCQB:TRYPF) signed a letter of intent with Massachusetts General Hospital (MGH) to fund and conduct a Phase 2a clinical trial investigating the effects of psilocybin-assisted psychotherapy in the treatment of patients aged 21+ suffering from Irritable Bowel Syndrome (IBS). According to Tryp, IBS is a common, chronic, and often debilitating condition with an estimated prevalence in the general population ranging from 4-5%. Industry research has demonstrated that a large percentage of IBS patients and gastroenterologists are dissatisfied with current treatments indicating an opportunity for a new approach.
Dr. Erin Mauney, the pediatric gastroenterology fellow at Massachusetts General Hospital leading the proposed study, said “There is tremendous potential for the treatment of debilitating IBS and other disorders of gut-brain interaction by utilizing the combined administration of psilocybin and psychotherapy. Our clinical study will examine how psilocybin-assisted psychotherapy may alter important brain networks involved in chronic pain and gastrointestinal-specific anxiety in IBS to bolster the neural flexibility in these patients and thereby reduce visceral hypersensitivity.”
Tryp has already demonstrated an interest in solving digestion and eating problems with psilocybin. The company has an ongoing Phase 2a clinical trial for the treatment of Binge Eating Disorder at the University of Florida and an upcoming Phase 2a clinical trial with the University of Michigan for the treatment of fibromyalgia, both of which are utilizing TRP-8802 (synthetic, oral psilocybin) to demonstrate efficacy in these indications. The market for IBS treatments is estimated to grow to $4.7 billion by 2030.
Jim Gilligan, PhD, Chief Executive Officer of Tryp Therapeutics, commented, “MGH is an ideal partner for Tryp to expand on its strategy of utilizing TRP-8802 (oral psilocybin) to explore the clinical potential of psilocybin-assisted psychotherapy in new indications. With positive results in this study, Tryp would look to continue clinical development in IBS with TRP-8803, our proprietary formulation of IV-infused psilocin, that alleviates numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. Our ultimate goal is providing even more favorable outcomes and relief to the millions of patients currently suffering from IBS and its associated disorders. With this agreement in place, we will be in a position to submit the relevant IND.”
The post Tryp Partners With Hospital For Psilocybin Study For IBS appeared first on Green Market Report.
psilocybin psychedelic therapeutics psychotherapy anxiety fund cse tryp therapeutics tryp research-
Psilocybin6 days ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics6 days ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics6 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics6 days ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Law & Regulation6 days ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psychedelics6 days ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psychedelics6 days ago
Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research
-
Law & Regulation6 days ago
Adastra reports record sales in 2023, but remains in the red